TG Therapeutics has announced that the United States Food and Drug Administration (FDA) approved Briumvi™ (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis (MS) in adults – including clinically isolated syndrome, relapsing-remitting MS, and active secondary-progressive MS. This medication is a monoclonal antibody that targets CD20, a protein found on the surface of B cells, and induces B-cell depletion within 24 hours. B cells are white blood cells shown to play a role in MS.
Read News ArticleCategory: Latest News
What’s New in MS Research – November 2022
Experts in every aspect of multiple sclerosis (MS) gathered in Amsterdam, The Netherlands, in late October 2022 to unveil research results and share ideas at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). With more than 1,200 bridges, the Dutch capital was an appropriate location for a meeting dedicated to connecting the findings from laboratory research and clinical trials to enhancements in patient care.
Read News ArticleIn Remembrance: Jack Burks, MD
On Friday, November 18, 2022, …
Read News ArticleWhat’s New in MS Research – September 2022
If there’s one theme that emerges from the study findings that follow, it’s how much people with multiple sclerosis (MS) can do to enhance their health and wellbeing. We know that can be a challenging task, as many aspects of the disease and its course remain beyond a person’s control. Nonetheless, the research summarized here provides abundant reason for encouragement.
Read News ArticleThe Multiple Sclerosis Association of America (MSAA) Launches Comprehensive Tool for the MS Community to Learn about Treatment Options
The Multiple Sclerosis Association of America (MSAA) is proud to announce the launch of the Ultimate MS Treatment Guide – a unique and comprehensive tool to help people with multiple sclerosis learn about the different FDA-approved disease-modifying therapies. This online resource for the MS community, which can be accessed at MStreatmentguide.org, has been developed by MSAA in collaboration with Wondros, a global creative agency.
Read News ArticleMSAA’s Publications Receive National Recognition
The Multiple Sclerosis Associa …
Read News ArticleWhat’s New in MS Research – July 2022
Hope filled the halls of the Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) during the first week of June, when MS clinicians, researchers, and advocates from across the country and abroad convened to exchange the latest findings in MS research.
Read News ArticleMSAA’s Blog and Publication Receive Digital Health Awards
The Multiple Sclerosis Associa …
Read News ArticleWhat’s New in MS Research – May 2022
Reviewed by MSAA Chief Medical …
Read News Article